Other myotonic disorders (symptomatic, chondrodystrophic, pseudomyotonia, etc.)Other Myotonic Disorders
📋 Contents and key points
1. History
ICD-10 G71.1 'Other myotonic disorders' is a category that includes a heterogeneous clinical group not falling under clearly classified myotonic diseases such as DM1, DM2, myotonia congenita (CLCN1), paramyotonia (SCN4A) and neuromyotonia (Isaacs). Schwartz-Jampel syndrome (SJS), one of the representative diseases in this group, entered the medical literature in 1962 when the American ophthalmologist Oscar Schwartz and neurologist Robert S. Jampel first described a syndrome of skeletal abnormalities with muscle stiffness. SJS is also called chondrodystrophic myotonia and is a rare syndrome combining skeletal abnormalities (short stature, multiple epiphyseal dysplasia, joint contractures, characteristic facies) with muscle stiffness. Its molecular cause was identified by Nicole et al. in 2001 as variants of the HSPG2 gene (encoding the protein perlecan). Symptomatic myotonia is myotonia secondarily induced by drugs such as statins, clofibrate and cholestyramine, electrolyte abnormalities, hypothyroidism, etc., and was gradually recognized as pharmacoepidemiology developed. Pseudomyotonia refers to a condition clinically similar to myotonia but without true myotonic discharges on EMG, and must be differentiated from rippling muscle disease or neuromyotonia.
2. Causes
Other myotonic disorders are broadly classified into three groups by cause.
Schwartz-Jampel syndrome (chondrodystrophic myotonia)
- Caused by pathogenic variants of the HSPG2 gene (1p36.1). HSPG2 encodes perlecan, a basement membrane heparan sulfate proteoglycan, a protein essential for the composition of the basement membranes of skeletal muscle, cartilage, bone and brain.
- Autosomal recessive inheritance. Loss-of-function variants are required in both HSPG2 alleles.
Symptomatic myotonia (drug or metabolic causes)
- Drug-induced: HMG-CoA reductase inhibitors (statins: simvastatin, rosuvastatin, etc.), clofibrate (fibrate lipid-lowering agent), cholestyramine, anthracycline anticancer drugs, chloroquine/hydroxychloroquine, β-blockers, etc. Statin-induced myotonia is rare but must be distinguished from myopathy.
- Metabolic and endocrine causes: hypothyroidism (hypothyroid myotonia, Hoffmann syndrome), adrenal insufficiency, electrolyte abnormalities (hypocalcemia, hypokalemia).
- Associated inflammatory myopathy: Rarely, myotonic discharges may be observed in polymyositis or dermatomyositis.
Pseudomyotonia
- A condition clinically similar to myotonia but without true myotonic discharges on EMG. It may be observed in rippling muscle disease, contracture, neuromyotonia and Brody disease (sarcoplasmic reticulum Ca-ATPase deficiency).
3. Genetics
Schwartz-Jampel syndrome
Autosomal recessive inheritance. Biallelic pathogenic variants of the HSPG2 gene (1p36.1). Various types, including deletion, missense, nonsense and splicing variants, have been reported. Incidence is higher in consanguineous families. Some genotype-phenotype correlation exists, and complete loss-of-function variants may present a more severe phenotype (SJS type 1B or the lethal form).
Symptomatic myotonia and pseudomyotonia
When not a genetic disease (drug or metabolic causes), genetic classification does not apply. However, there are reports that an underlying genetic predisposition (e.g., CLCN1 carrier status) can increase the risk of developing drug-induced myotonia. Brody disease is an autosomal recessive genetic disease caused by ATP2A1 gene variants.
| Disease | Gene | Mode of inheritance | Key features |
| Schwartz-Jampel syndrome | HSPG2 | Autosomal recessive | Skeletal abnormalities + myotonia |
| Brody disease | ATP2A1 | Autosomal recessive | Delayed relaxation after exercise, normal EMG |
| Symptomatic myotonia | Not applicable | Acquired | Drug or metabolic causes |
| Hypothyroidism-related | Not applicable | Acquired | Recovers with thyroid treatment |
4. General epidemiology
Because other myotonic disorders are a heterogeneous group, it is difficult to express the overall prevalence as a single figure. Schwartz-Jampel syndrome is so rare that fewer than several hundred cases have been reported worldwide. Prevalence is equal between sexes, and it is reported relatively more often in regions where consanguineous marriage is frequent, such as the Middle East and India. Awareness of symptomatic (drug-induced) myotonia is increasing in clinical practice as statin prescriptions increase, but overall prevalence is low. While the incidence of statin-induced myopathy is high at about 10%, the proportion accompanied by myotonic discharges is much lower. Hypothyroidism-related myotonia (Hoffmann syndrome) is very rare relative to the prevalence of hypothyroidism itself.
5. Pathophysiology
Pathogenesis of Schwartz-Jampel syndrome
Perlecan, encoded by the HSPG2 gene, is a heparan sulfate proteoglycan of the extracellular matrix (ECM) and a component of the basement membrane of the neuromuscular junction (NMJ). Perlecan anchors acetylcholinesterase (AChE) at the NMJ. With HSPG2 loss-of-function variants, AChE is not normally anchored at the NMJ, resulting in excessive accumulation of acetylcholine and thereby continuous muscle activity. At the same time, abnormal basement membrane composition in cartilage and bone results in skeletal dysplasia.
Pathogenesis of symptomatic myotonia
- Statin-induced: decreased cholesterol in the muscle cell membrane → reduced ClC-1 chloride channel function → increased membrane hyperexcitability. Muscle cell dysfunction through inhibition of the isoprenylation pathway also contributes.
- Hypothyroidism: thyroid hormone deficiency → impaired function of muscle cell membrane ion channels and ATP-dependent ion pumps → membrane potential instability → induction of myotonic discharges.
- Hypocalcemia: decreased extracellular Ca²⁺ → lowered sodium channel activation threshold → membrane hyperexcitability.
Pathogenesis of pseudomyotonia
- Brody disease: loss of function of ATP2A1 (sarcoplasmic reticulum Ca²⁺-ATPase, SERCA1) → impaired Ca²⁺ reuptake into the sarcoplasmic reticulum → delayed relaxation. No true myotonic discharges on EMG.
- Rippling muscle disease: CAV3 (caveolin-3) or PTRF (CAVIN1) variants → abnormal muscle contraction induced by mechanical stimuli. Electrically silent on EMG.
6. Symptoms
Schwartz-Jampel syndrome
- Muscle symptoms: Generalized muscle stiffness and rigidity. Delayed relaxation after voluntary movement. Characteristic facies due to facial muscle stiffness (narrow palpebral fissures, small mouth due to perioral muscle stiffness). Swallowing difficulty, dysarthria.
- Skeletal abnormalities: Short stature, multiple epiphyseal dysplasia, scoliosis, joint contractures, hip dysplasia, possible microcephaly.
- Ophthalmologic findings: Ptosis, blepharospasm, proptosis, myopia.
- Other: Symptoms present from birth or in infancy. Not progressive, but functional changes with age are possible in some patients.
Symptomatic myotonia (statin-induced)
- Muscle stiffness and pain develop within weeks to months after starting a statin.
- May be accompanied by muscle weakness (myopathic component).
- CK may be elevated or normal.
- Symptoms resolve within weeks after stopping the statin.
Hypothyroidism-related (Hoffmann syndrome)
- Muscle stiffness, muscle hypertrophy, muscle weakness, cramps, CK elevation.
- May resemble myotonic dystrophy, but symptoms resolve after thyroid hormone replacement.
Pseudomyotonia (Brody disease)
- Delayed muscle relaxation after exercise. Delayed relaxation of facial, upper limb and lower limb muscles, especially after high-intensity exercise. May be accompanied by muscle pain.
- Similar to the warm-up phenomenon — improves with repeated exercise. No cardiac or ocular involvement.
7. Signs
Schwartz-Jampel syndrome
- Characteristic facies: narrow palpebral fissures (blepharophimosis), short neck, small mouth, jaw abnormality.
- Muscle stiffness: sustained muscle contraction induced by percussion or physical contact.
- Skeletal abnormalities: confirmation of reduced height, scoliosis, hip dysplasia and joint contractures.
- EMG: continuous spontaneous action potentials, myotonic discharges (including high-frequency repetitive discharges). Pattern similar to muscle stiffness.
Symptomatic myotonia
- Percussion myotonia: may be mild or absent.
- Elevated serum CK (especially statin-induced).
- Hypothyroidism-related: delayed relaxation of tendon reflexes, myxedema findings.
Pseudomyotonia (Brody disease)
- Exercise-induced delayed relaxation is observed, but EMG is electrically silent (electrically silent contracture) — the key point of differentiation from true myotonia.
- Percussion myotonia: absent.
Common laboratory findings
- Serum CK: variable (may be elevated in Schwartz-Jampel syndrome, normal or mildly elevated in Brody disease).
- Thyroid function tests: checking for hypothyroidism is essential in symptomatic myotonia.
8. Screening
- Clinical history:
- Muscle stiffness + skeletal abnormalities from birth → suspect Schwartz-Jampel syndrome.
- Muscle stiffness developing while taking a statin or fibrate → suspect drug-induced.
- Muscle stiffness + weight gain, bradycardia, fatigue, constipation → suspect hypothyroidism-related.
- Delayed relaxation after exercise, normal EMG → suspect pseudomyotonia (Brody disease, etc.).
- Serum CK: screening for myopathy and myotonia.
- Thyroid function tests (TSH, Free T4): differentiation of secondary causes.
- Serum electrolytes (Ca, K, Mg): differentiation of causes related to electrolyte abnormalities.
- EMG (needle electrode): key to confirming true myotonic discharges vs. differentiating pseudomyotonia (electrical silence).
- Medication history review: check for use of drugs that can induce myotonia.
9. Diagnosis
Schwartz-Jampel syndrome
- Clinical diagnosis: characteristic skeletal abnormalities + myotonic symptoms + characteristic facies.
- Molecular genetic confirmation: HSPG2 gene sequencing. Confirmation of biallelic pathogenic variants.
- Radiological examination: whole-body skeletal radiography (evaluation of epiphyseal abnormalities, scoliosis, etc.).
- EMG: high-frequency repetitive discharges, continuous motor unit activity (pattern similar to muscle stiffness). Confirmation of muscle fiber origin.
- Muscle biopsy: nonspecific myopathic changes. Reduced protein expression can be confirmed by perlecan immunohistochemistry.
Symptomatic myotonia and metabolic causes
- Diagnosis is confirmed by identification and correction of the underlying cause (hypothyroidism, hypocalcemia, drugs) followed by resolution of symptoms.
- EMG: confirmation of myotonic discharges (true myotonic discharges may be seen even in symptomatic myotonia).
Pseudomyotonia (Brody disease)
- EMG: electrical silence during exercise-induced contracture (electrically silent) — the key finding.
- Exercise testing: normal rise in lactate on the forearm ischemic exercise test (confirming a sarcoplasmic reticulum disorder).
- ATP2A1 gene testing: confirmation of Brody disease.
- Muscle biopsy: reduced SERCA1 protein expression.
Summary of differential diagnosis
| Disease | EMG | warm-up | Skeletal abnormalities | Confirmation |
| Schwartz-Jampel syndrome | Myotonic discharges + continuous motor unit activity | None | Present | HSPG2 |
| Brody disease | Electrical silence | Present | None | ATP2A1 |
| Symptomatic (statin) | Myotonic discharges (mild) | Possible | None | Resolves after drug discontinuation |
| Hypothyroidism | Myotonic discharges possible | Possible | None | TSH↑, FT4↓ |
10. Treatment
Schwartz-Jampel syndrome
- Membrane-stabilizing drugs: Carbamazepine, mexiletine, phenytoin, etc. may be used to relieve muscle stiffness. Efficacy has been reported in some cases, but evidence from large clinical trials is limited.
- Botulinum toxin: efficacy reported with local injection for blepharospasm and stiffness of specific muscles.
- Orthopedic treatment: surgery to correct joint contractures, scoliosis correction, hip dysplasia surgery.
- Ophthalmologic treatment: ptosis correction, correction of refractive errors.
- Rehabilitation: physical therapy and occupational therapy to maintain joint range of motion and improve function.
- Nutritional support: optimization of nutritional status in patients with swallowing difficulty.
Symptomatic (drug-induced) myotonia
- Discontinuation of the causative drug: immediate or stepwise discontinuation of the causative drug, such as statins or fibrates. Symptoms mostly resolve within weeks.
- In patients with hyperlipidemia who truly require a statin, consider switching to a different statin or substituting a PCSK9 inhibitor.
- Short-term use of carbamazepine or mexiletine is possible while myotonic symptoms persist.
Hypothyroidism-related
- Thyroid hormone replacement (levothyroxine): myotonic symptoms resolve within weeks to months after treatment. No additional myotonia treatment needed.
Pseudomyotonia (Brody disease)
- Xanthine oxidase inhibitors: efficacy of dantrolene reported in some cases.
- Adjustment of exercise intensity: avoid high-intensity exercise. Gradual warm-up protocol.
- No established drug treatment at present.
11. Prognosis
The prognosis of other myotonic disorders differs greatly by underlying disease. Schwartz-Jampel syndrome is nonprogressive, but functional limitation and complications due to skeletal abnormalities (progression of scoliosis, reduced respiratory function) can be long-term problems. Function can be maintained with appropriate orthopedic intervention and rehabilitation. Most patients have a normal or near-normal lifespan, but the prognosis may become poor with severe skeletal abnormalities or respiratory complications. Symptomatic (drug-induced) myotonia mostly recovers completely after discontinuation of the causative drug, and the prognosis is good. Hypothyroidism-related myotonia is also expected to recover completely with appropriate hormone replacement. Brody disease (pseudomyotonia) is not progressive and has no life-threatening complications, so the prognosis is good, but limited exercise capacity can affect quality of life.
12. Prevention
- Genetic counseling for Schwartz-Jampel syndrome: Explanation of the autosomal recessive mode of inheritance. When both parents are carriers, the risk to each child is 25%. In families with an identified HSPG2 variant, preimplantation genetic diagnosis (PGT-M) and prenatal diagnosis are possible.
- Prevention of drug-induced myotonia:
- When prescribing statins, regularly monitor for muscle symptoms (stiffness, pain, weakness).
- In patients with a history of myotonia or muscle disease, start statins at a low dose and follow closely.
- Recognize the increased risk of drug induction in patients with underlying CLCN1 carrier status or latent myotonia.
- Early diagnosis of hypothyroidism: prevention of myotonia-related complications through early detection and treatment with regular TSH testing.
- Correction of electrolyte abnormalities: prevention and early correction of electrolyte abnormalities that can induce myotonia, such as hypocalcemia and hypokalemia.
- Precautions during surgery and anesthesia: In patients with Schwartz-Jampel syndrome, inform the anesthesiology team in advance of difficult airway intubation under general anesthesia, caution with depolarizing muscle relaxants, and the risk of malignant hyperthermia-like reactions.
13. References
- Nicole S, Davoine CS, Topaloglu H, et al. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet. 2000;26(4):480–483. PMID: 11101850
- Aberfeld DC, Hinterbuchner LP, Schneider M. Myotonia, dwarfism, diffuse bone disease and unusual ocular and facial abnormalities (a new syndrome). Brain. 1965;88(2):313–322. PMID: 5828997
- Doriguzzi C, Palmucci L, Mongini T, Chiado-Piat L, Maniscalco M. Schwartz-Jampel syndrome: a new variant (type II). Eur Neurol. 1993;33(1):63–68. PMID: 8422819
- Rajpal MK, Sedki FK, Eid TJ. Statin-induced myopathy in a patient with Schwartz-Jampel syndrome. J Pharm Pract. 2024;37(1):227–230. PMID: 37931642
- Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993;5(1):51–55. PMID: 8220423
- Brody IA. Muscle contracture induced by exercise. A syndrome attributable to decreased relaxing factor. N Engl J Med. 1969;281(4):187–192. PMID: 4308552
- Taylor RG, Layzer RB, Davis HS, Fowler WM Jr. Continuous muscle fiber activity in the Schwartz-Jampel syndrome. Electroencephalogr Clin Neurophysiol. 1972;33(5):497–509. PMID: 4117558
- Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am. 2013;24(1):193–207. PMID: 23177040
- Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Trivedi JR. Nondystrophic myotonias. Neurol Clin. 2014;32(3):801–815. PMID: 25037089
- Fialho D, Bhatt DL, Hanna MG, Hanna MG. Non-dystrophic myotonias: a consensus guide to diagnosis and management. Pract Neurol. 2018;18(6):484–498. PMID: 29959219